Exploratory Bioavailability of Two Formulations of Gliclazide MR Tablets 120 mg (I.R.I.S.) in Healthy Volunteers Under Fed and Fasting Conditions.

2023-507802-15-00 Protocol S005190-170 Human pharmacology (Phase I) - Other Ended

Start 7 Nov 2023 · End 20 Dec 2023 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol S005190-170

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 68
Countries 1
Sites 1

Type 2 diabetes mellitus

Key facts

Sponsor
Institut De Recherches Internationales Servier IRIS
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trial duration
7 Nov 2023 → 20 Dec 2023
Decision date (initial)
2023-11-03
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Type 2 diabetes mellitus

VersionLevelCodeTermSystem organ class
21.1 PT 10067585 Type 2 diabetes mellitus 100000004861

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Institut De Recherches Internationales Servier IRIS

Sponsor organisation
Institut De Recherches Internationales Servier IRIS
Address
22 Route 128
City
Gif Sur Yvette
Postcode
91190
Country
France

Scientific contact point

Organisation
Institut De Recherches Internationales Servier IRIS
Contact name
Valérie Brunet

Public contact point

Organisation
Institut De Recherches Internationales Servier IRIS
Contact name
Regulatory Affairs & Pharmacovigilance Management

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Portugal Ended 68 1
Rest of world 0

Investigational sites

Portugal

1 site · Ended
Blueclinical Investigacao E Desenvolvimento Em Saude Lda.
Medical Management, East Wing, Rua De Sarmento De Beires 153 3rd Floor 4 Floor, Porto

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Portugal 2023-11-07 2023-12-20 2023-11-07 2023-11-14

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-09-08 Portugal Acceptable
2023-10-31
2023-11-03